Curated News
By: NewsRamp Editorial Staff
September 09, 2026
Helus Pharma CEO to Present at Major Investment Conference
TLDR
- Helus Pharma CEO presents at H.C. Wainwright conference, offering investors insight into psychedelic drug candidates.
- Helus Pharma develops synthetic serotonin agonists targeting neuroplasticity, with HLP003 in Phase 3 for depression.
- Helus Pharma aims to treat depression and anxiety, potentially improving millions of lives with innovative therapies.
- Helus Pharma, formerly Cybin, uses psychedelic-inspired molecules for mental health breakthroughs.
Impact - Why it Matters
This news matters because it highlights Helus Pharma's active engagement with the investment community and the progress of its mental health treatments. For investors, the upcoming presentation offers an opportunity to gain insights into the company's strategy and clinical developments. For patients and healthcare providers, the advancement of novel serotonergic agonists like HLP003 and HLP004 could lead to new, more effective treatments for depression and anxiety, potentially improving outcomes for millions suffering from these conditions. The company's focus on neuroplasticity represents a promising frontier in psychiatric care.
Summary
Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company formerly known as Cybin Inc., is set to present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026. CEO Michael Halstead will participate in a fireside chat on September 14 at 9 a.m. EDT, which will be webcast live and later available on the company's investor relations website. This appearance underscores Helus Pharma's commitment to advancing its pipeline of novel serotonergic agonists (NSAs) designed to treat mental health conditions such as depression and anxiety, which represent a significant unmet medical need.
Helus Pharma is developing HLP003, a proprietary NSA in Phase 3 clinical trials for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. FDA. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. The company's innovative approach focuses on activating serotonin pathways to promote neuroplasticity, aiming to provide durable improvements in mental health. With operations in Canada, the United States, the United Kingdom, and Ireland, Helus Pharma is dedicated to transforming the mental health treatment landscape.
The full press release can be accessed at https://ibn.fm/1HSIo. For more information about Helus Pharma, visit www.helus.com or follow the team on social media. The company's newsroom at https://ibn.fm/HELP provides the latest updates. The press release was disseminated by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which offers press release syndication and corporate communications solutions to reach a broad audience of investors and the public.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma CEO to Present at Major Investment Conference
